Ron Bose, MD, PhD

Ron Bose, MD, PhD, discusses the rationale for a trial of neratinib plus alpelisib for patients with HER2-positive breast cancer.

Ron Bose, MD, PhD, discusses the challenge of drug resistance due to mutations for patients with HER2-positive breast cancer.

Ron Bose, MD, PhD, discusses the importance of computer simulations to develop treatments for patients with HER2-positive breast cancer as established by a recent study.